ABBV
AbbVie’s latest pipeline shopping trip
AbbVie is back in deal mode, this time licensing a portfolio of pain compounds from China’s Haisco Pharmaceutical Group. The headline number is the kind that makes you blink twice: up to $745 million if all the milestones get hit.
What AbbVie is actually buying
This isn’t a full-blown acquisition — it’s more like getting the keys to the car, not the whole dealership. AbbVie will have the right to develop, manufacture, and commercialize the assets outside mainland China, Hong Kong, and Macau.
The economics are split between:
- $30 million upfront
- Up to $715 million tied to development, regulatory, and commercial milestones
Why investors should care
AbbVie has been on a recent shopping spree to pad out its post-Humira future. When a giant pharma company keeps writing checks for outside-the-box assets, it usually means one thing: the internal pipeline still needs backup singers.
And this comes right after a few other big licensing moves, including the January RemeGen deal and the alveltamig agreement. Translation: AbbVie is trying to stack enough future shots on goal so the next decade doesn’t feel like a cliff dive.
Big picture
For shareholders, the immediate question isn’t whether AbbVie can announce deals — it clearly can. It’s whether these expensive bets can turn into real drugs, real revenue, and real margin instead of just very pricey hope. Until then, this is classic big-pharma chess: spend now, worry later.